SPR Therapeutics said today that it launched its FDA-cleared Sprint Endura single-lead peripheral nerve stimulation system intended for treating complex regional pain syndrome.
Complex regional pain syndrome is a chronic pain condition affecting the limbs that can be caused by trauma, injury or surgery. The Cleveland-based company said that the device was used in its first commercial procedure by Dr. Marc Huntoon of VCU Medical Center.
“I have been treating complex regional pain syndrome, a condition known as CRPS, for nearly three decades. In my experience, patients suffering chronic pain benefit from early intervention with peripheral nerve stimulation. Now that there is a less invasive percutaneous option, PNS can more easily be deployed sooner in the care continuum. In my experience, this new method of peripheral nerve stimulation is generally safe, effective and minimally invasive,” Dr. Huntoon of VCU Medical Center’s outpatient Neuroscience, Orthopaedic and Welless Center said in a prepared statement.
The Sprint system is a minimally invasive peripheral nerve stimulation system intended for use early in the continuum of care, SPR Therapeutics said.
“We are pleased to see accelerated adoption of the latest version of our Sprint Peripheral Nerve Stimulation system following its recent FDA clearance. It is gratifying to see the Sprint system being prescribed earlier in the disease process for a broad range of pain disorders, including CRPS, due to our technology’s minimally invasive and patient-friendly features,” prez & CEO Maria Bennett said in a press release.
Early last month, SPR Therapeutics said that it received $10 million from two new grants and a contract from the US Dept. of Defense, all to support its percutaneous peripheral nerve stimulation therapy intended as a non-opioid pain relief therapy for both acute and chronic pain.
